Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models. (PubMed, Cancers (Basel)) - Sep 27, 2025 - " Potency and selectivity of ADT-007 were benchmarked against bortezomib (proteasome inhibitor) and YM155 (survivin inhibitor) using high-content imaging and ATP-based luminescence assays...This study also underscores the translational utility of 3D BEST models for preclinical drug response assessment. Further validation in patient-derived BEST is necessary to evaluate the potential of ADT-007 in clinical settings."
Journal • Preclinical • Colorectal Cancer • Oncology • Solid Tumor • ANXA5 • KRAS
|
|
Adam B Keeton; Allan Tsung; Chelsea L Crawford; Daniela D De Nobrega; Donald J Buchsbaum; Gary A Piazza; Karim I Budhwani; Logan C Eiler; Parmanand Ahirwar; Sonika Nallapu; Urvi P Rawal; Xi Chen; Yulia Y Maxuitenko
|